Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Iovance Biotherapeutics (IOVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$24.42 | $34.00 | $10.00 | 110.15% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Iovance Biotherapeutics comes to $24.42. The forecasts range from a low of $10.00 to a high of $34.00. The average price target represents an increase of 110.15% from the last closing price of $11.62.
Analyst Price Targets (12)
Broker Rating
Iovance Biotherapeutics currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, 12 are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 92.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/IOVA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 13 | 13 | 13 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
8/12/2024 | Truist Securities | Asthika S Goonewardene | Strong Buy | Strong Buy |
8/11/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/29/2024 | Piper Sandler | Joseph M Catanzaro | Hold | Hold |
7/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
6/3/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/1/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Andrea Tan | Strong Buy | Strong Buy |
2/19/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
10/2/2023 | Guggenheim Securities | Kelsey Goodwin | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 14 |
Average Target Price | $24.42 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.33 |